CST, 39862S, CRAD Antibody

Polyclonal Antibody for studying CRAD. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, CRAD Antibody (CST #39862) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity CRAD Antibody recognizes endogenous levels of total CRAD protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro200 of human CRAD protein. Antibodies are purified by peptide affinity chromatography. Background Cancer-related regulator of actin dynamics (CRAD, also CRACD, KIAA1211) regulates actin polymerization and epithelial integrity by sequestering actin capping proteins CAPZA and CAPZB. CRAD stabilizes the β-catenin/E-cadherin complex. Loss of CRAD allows β-catenin to activate wnt signaling (1). While CRAD was identified as a tumor suppressor downregulated in colorectal cancer, its expression is upregulated in other human cancers, including non-small cell lung cancer (NSCLC) and breast cancer (1-3). In NSCLC cells, downregulation of CRAD inhibits proliferation and increases the rate of apoptosis (2). Mutation of CRAD in small cell lung cancer (SCLC) may serve as a prognostic marker for overall survival (4). Alternate Names Cancer-related regulator of actin dynamics; Capping protein inhibiting regulator of actin dynamics; capping protein inhibiting regulator of actin dynamicsp; Capping protein-inhibiting regulator of actin dynamics; CRACD; CRAD; DKFZp564H1363; KIAA1211; RP11-646I6.2 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 200 SOURCE: Rabbit